In This Story HIMS -0.39% NVO +0.31% LLY +0.01% The millennial-skewed telehealth platform Hims & Hers ( HIMS -0.39% ) announced Monday that it will start offering customers a generic version of liraglutide, an older GLP-1 weight loss drug, next year. The news comes as some patients still struggle to fill prescriptions of the most advanced branded GLP-1 treatments on the market like Zepbound, Wegovy and Ozempic. Suggested Reading Tesla stock is soaring as Elon Musk looks to benefit from Donald